

03-13-00

Case: 20296-2001301

Internal Number: 4-127-1000/P1/CONT/SYS

Serial Number: 08/704,445

GA 6 1600
GPA
S

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: "Assistant Commissioner for Patents, Washington, DC 20231," on March 10, 2000.

Christa Carter
Christa Carter

IN THE UNITED STATES PATENT AND TRADEMARK DEPARTMENT

Applicant:	B. Chen, et al.)	Group Art Unit: 1632
)	
Serial No.:	08/704,445)	Examiner: K.M. Hauda
)	
Filing Date:	August 26, 1996)	
)	
For:	Methods of Preventing Depletion Of Non-Autologous Hematopoietic Cells and Animal Model System for Use Thereof)	
)	



TRANSMITTAL LETTER

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, DC 20231

Dear Sir:

Enclosed please find the following:

- a) Correspondence Address Indication Form;
- b) Petition for Extension of Time (in duplicate)
- c) Continued Prosecution Application Request Transmittal (in duplicate);
and
- d) Postcard Receipt.

The Assistant Commissioner is hereby authorized to charge any fees that may be required by this transmittal, or to credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Melissa A. Shaw

Melissa A. Shaw
Attorney for Applicant(s)
Reg. No. 38,301

March 10, 2000

SYSTEMIX, INC.
NOVARTIS CORPORATION
Patent Department
1651 Page Mill Road
Palo Alto, California 94304
Tel. No. 650-813-4153

TC 1600 MAIL ROOM

RECEIVED
MAR 17 2000



CASE 20296-2001301
Internal Number: 4-127-1000/P1/CONT/SYS

RECEIVED
MAR 17 2000
TC 1600 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

B. Chen, et al.

APPLICATION NO: 08/704,445

FILED: August 26, 1996

FOR: Methods of Preventing Depletions of Non-Autologous Hematopoietic Cells and Animal Model System for Use Thereof

Assistant Commissioner for Patents
Washington, D.C. 20231

CORRESPONDENCE ADDRESS INDICATION FORM

Sir:

In the above-identified application, please recognize the following address as the correspondence address:

**Melissa A. Shaw
Systemix, Inc.
Patent Department
1651 Page Mill Road
Palo Alto, CA 94304**

The undersigned attorney is of record.

Respectfully submitted,

Melissa A. Shaw


**Melissa A. Shaw
Attorney for Applicant
Reg. No. 38,301
Phone No. (650) 813-4153**

Systemix, Inc.
Patent Department
1651 Page Mill Road
Palo Alto, CA 94304

Date: March 10, 2000

34

Docket Number Internal Number:	20296-206/301 4-127-1000/P1/CONT/SYS
FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EL466277413US Express Mail Label Number	March 10, 2000 Date of Deposit



Address to: Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

This is a request for a **continuation** application under 37 CFR §1.53(d) (continued prosecution application (CPA)) of prior Application No. 08/704,445, filed on August 26, 1996.

Applicant: B. CHEN, ET AL.

Title: METHODS OF PREVENTING DEPLETION OF NON-AUTOLOGOUS HEMATOPOIETIC CELLS AND ANIMAL MODEL SYSTEM FOR USE THEREOF

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR §1.51(b), or (2) the national stage of an international application in compliance with 35 USC §371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC §154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR §1.53(d), but must be filed under 37 CFR §1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR §1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 USC §122 to the extent that any member of the public who is entitled under the provisions of 37 CFR §1.14 to access to, copies of, or information concerning , the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 USC §120 STATEMENT: In a CPA, no references to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 USC §120 and to every application assigned the application number identified in such request, 37 CFR §1.78(a).

<ol style="list-style-type: none"> 1. <input type="checkbox"/> Enter the unentered amendment previously filed on the prior nonprovisional application. 2. <input type="checkbox"/> A Preliminary Amendment is enclosed. 3. <input type="checkbox"/> This application is filed by fewer than all the inventors named in the prior application 37 CFR §1.53(d)(4). DELETE the following inventor(s) named in the prior nonprovisional application: 4. <input type="checkbox"/> A new Declaration and Power of Attorney is enclosed. 5. <input type="checkbox"/> An Information Disclosure Statement (IDS) is enclosed: <ol style="list-style-type: none"> a. <input type="checkbox"/> PTO-1449 or similar form b. <input type="checkbox"/> Copies of IDS citations 6. <input checked="" type="checkbox"/> A return receipt postcard is enclosed. 	under 37 CFR §1.116 in 0870445 00000086 190134 690.00 CH 252.00 CH 234.00 CH 03/16/2000 WMAH11 01 FC:131 02 FC:103 03 FC:102
---	--

7. The right to elect an invention or species that is different from that elected in parent Application No. 08/704,445 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.

8. Other:

Filing fee calculation:

Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims

Basic Filing Fee							\$ 760
Multiple Dependent Claim Fee (\$ 260)							\$
	For	Number Filed		Number Extra		Rate	
Extra Claims	Total Claims	34	-20	14	x	\$ 18	= \$ 252
	Independent Claims	6	-3	3	x	\$ 78	= \$ 234
TOTAL FILING FEE							\$ 1,246

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$1,246. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to:

the present correspondence address for prior Application No. 08/704,445
 Melissa A. Shaw
Systemix, Inc.
Patent Department
1651 Page Mill Road
Palo Alto, CA 94304

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (650) 813-4131.

Respectfully submitted,



Melissa A. Shaw
Attorney for Applicant
Reg. No. 38,301
Tel. No. (650) 813-4153

Date: March 10, 2000